HBSP (USA)
-
Perfect Storm over Zurich Airport (A)
Tushman, Michael L.; Kiron, DavidCase HBS-408023-ELeadership and People ManagementJosef Felder, CEO of Zurich Airport, faces several crises as he tries to transform the Airport from a slow-moving, conflict-ridden, government-owned entity into a privatized, world-class airport.Starting at €8.20
-
Perfect Storm over Zurich Airport (A) & (B), Teaching Note
Tushman, Michael L.; Kiron, DavidTeaching Note HBS-411015-ELeadership and People ManagementTeaching Note for 408023 and 408058.Starting at €0.00
-
Bernd Beetz: Creating the New Coty
Jones, Geoffrey G.; Kiron, DavidCase HBS-808133-EEntrepreneurshipConsiders the creation of one of the world's largest beauty and fragrance companies by Bernd Beetz, appointed chief executive of Coty Inc. in 2001. The case opens with the creation of a new Russian subsidiary in the wake of the global financial crisis, and examines how a virtually new company was created over the previous years. In 1990 the German consumer goods company Benkiser began acquiring fragrance and cosmetics brands with the intent of de...Starting at €8.20
-
Hema Hattangady and Conzerv (A) & (B), Teaching Note
Tushman, Michael L.; Kiron, DavidTeaching Note HBS-411014-ELeadership and People ManagementTeaching Note for 409022 and 411012.Starting at €0.00
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
Hema Hattangady and Conzerv (B)
Tushman, Michael L.; Kiron, DavidCase HBS-411012-ELeadership and People ManagementStarting at €5.74
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74